Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization

doi:10.3748/wjg.v21.i18.5582

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6766)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

387

WORD

243

HTML

3421

Figures (1-2)

150

Tables (1-5)

146

Sum=4347

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

918

Download

1501

Sum=2419

May 14, 2015 (publication date) through Apr 22, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 14, 2015; 21(18): 5582-5590
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5582

Table 1 Inflammation-based prognostic scores

Scoring systems	Score
Glasgow Prognostic Score
CRP ( ≤ 10 mg/L) and albumin (≥ 35 g/L)	0
CRP ( ≤ 10 mg/L) and albumin (< 35 g/L)	1
CRP (> 10 mg/L) and albumin (≥ 35 g/L)	1
CRP (> 10 mg/L) and albumin (< 35 g/L)	2
Modified Glasgow Prognostic Score
CRP ( ≤ 10 mg/L) and albumin (≥ 35 g/L)	0
CRP ( ≤ 10 mg/L) and albumin (< 35 g/L)	0
CRP (> 10 mg/L)	1
CRP (> 10 mg/L) and albumin (< 35 g/L)	2
Neutrophil-lymphocyte ratio
Neutrophil count:lymphocyte count < 3:1	0
Neutrophil count:lymphocyte count ≥ 3:1	1
Plt-lymphocyte ratio
Plt count:lymphocyte count < 150:1	0
Plt count:lymphocyte count ≥ 150:1	1
Plt count:lymphocyte count > 300:1	2
Prognostic index
CRP ( ≤ 10 mg/L) and WBC ( ≤ 11 × 10⁹/L)	0
CRP ( ≤ 10 mg/L) and WBC (> 11 × 10⁹/L)	1
CRP (> 10 mg/L) and WBC ( ≤ 11 × 10⁹/L)	1
CRP (> 10 mg/L) and WBC (> 11 × 10⁹/L)	2
Prognostic Nutritional Index
Albumin (g/L) × total lymphocyte count × 10⁹/L ≥ 45	0
Albumin (g/L) × total lymphocyte count × 10⁹/L < 45	1

CRP: C-reactive protein; Plt: Platelet; WBC: White blood cell count.

Table 2 Baseline characteristics for hepatocellular carcinoma patients undergoing transarterial chemoembolization (n = 224)

Variables	Value
Age (yr)	53 (23-80)
Sex (M/F)	199/25
WBC (× 10⁹/L)	6.6 (2.1-24.6)
Neutrophil count (× 10⁹/L)	4.2 (0.7-13.6)
Lymphocyte count (× 10⁹/L)	1.5 (0.3-4.8)
CRP (mg/L)	21.1 (0.2-218.3)
PLT count (× 10⁹/L)	182 (23-548)
ALT (U/L)	55.6 (8.0-304.0)
AST (U/L)	76.3 (20.2-472.6)
Albumin (g/L)	38.9 (7.6-79.4)
Total serum bilirubin (mmol/L)	18.0 (4.8-222.9)
ALP (IU/L)	148.7 (13.0-574.6)
AFP (ng/mL)	25828.4 (1.3-1210000.0)
AFU (U/L)	43.8 (12.6-992.0)
Diameter of largest lesion (cm)	9.2 (1.4-20.0)
Tumor number (solitary/multiple)	71/153
Vascular invasion (absent/present)	149/75
Child-Pugh grade (A/B)	208/16
GPS (0/1/2)	99/101/24
Modified GPS (0/1/2)	115/85/24
NLR (0/1)	108/116
PLR (0/1/2)	156/57/11
PI (0/1/2)	115/102/7
PNI (0/1)	154/70
TNM stage (I/II/IIIa/IIIb/IVa/IVb)	44/24/71/52/5/28
CLIP score (0/1/2/3/4/5)	19/56/70/43/34/2
BCLC stage (A/B/C)	10/124/90

AFP: Alpha-fetoprotein level; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFU: Alpha-L-fucosidase; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; CRP: C-reactive protein; GPS: Glasgow Prognostic Score; NLR: Neutrophil-lymphocyte ratio; PI: Prognostic Index; PLR: Platelet-lymphocyte ratio; PNI: Prognostic Nutritional Index; TNM: Tumor-node-metastasis; WBC: White blood cell count. Data are presented as mean (range) or n.

Table 3 Univariate and multivariate analyses of overall survival for hepatocellular carcinoma patients undergoing transarterial chemoembolization (n = 224)

Variable	Univariate analysis	Multivariate analysis
Variable	P value	HR (95%CI)	P value
Age (< 60/≥ 60 yr)	0.008
Sex (M/F)	0.118
WBC ( ≤ 10/> 10 × 10⁹/L)	0.094
Neutrophil count ( ≤ 7/> 7 × 10⁹/L)	0.038
Lymphocyte count ( ≤ 0.8/> 0.8 × 10⁹/L)	0.088
CRP ( ≤ 8/> 8 mg/L)	< 0.001
PLT count ( ≤ 100/> 100 × 10⁹/L)	0.472
ALT ( ≤ 40/> 40 U/L)	0.002	1.005 (1.001-1.009)	0.008
AST ( ≤ 45/> 45 U/L)	< 0.001
Albumin ( ≤ 35/> 35 g/L)	0.208
Total bilirubin ( ≤ 20.5/> 20.5 mmol/L)	< 0.001
ALP ( ≤ 110/> 110 IU/L)	< 0.001
AFP ( ≤ 400/> 400 ng/ml)	< 0.001
AFU ( ≤ 40/> 40 U/L)	0.042
Diameter of largest lesion (< 8/≥ 8 cm)	< 0.001
Tumor number (solitary/multiple)	0.025
Vascular invasion (absent/present)	< 0.001
Child-Pugh grade (A/B)	0.030
GPS (0/1/2)	< 0.001	1.697 (1.325-2.174)	< 0.001
Modified GPS (0/1/2)	< 0.001
NLR (0/1)	0.009
PLR (0/1/2)	0.553
PI (0/1/2)	< 0.001
PNI (0/1)	0.573
TNM stage (I/II/IIIa/IIIb/IVa/IVb)	< 0.001
CLIP score (0/1/2/3/4/5)	< 0.001	1.297 (1.1-1.53)	0.002
BCLC stage (A/B/C)	< 0.001

AFP: Alpha-fetoprotein level; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFU: Alpha-L-fucosidase; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; CLIP: Cancer of the Liver Italian Program; CRP: C-reactive protein; GPS: Glasgow Prognostic Score; HR: Hazard ratio; NLR: Neutrophil-lymphocyte ratio; PI: Prognostic Index; PLR: Platelet-lymphocyte ratio; PLT: Platelet; PNI: Prognostic Nutritional Index; TNM: Tumor-node-metastasis; WBC: White blood cell count.

Table 4 Comparison of the area under the curve between inflammation-based prognostic scores and staging systems

Period	AUC	95%CI	P value
6-mo
GPS	0.702	0.630-0.773	< 0.001
mGPS	0.699	0.627-0.770	< 0.001
PI	0.681	0.609-0.754	< 0.001
NLR	0.582	0.505-0.659	0.410
PNI	0.561	0.482-0.640	0.126
PLR	0.531	0.385-0.629	0.436
TNM	0.649	0.575-0.723	< 0.001
BCLC	0.635	0.559-0.712	0.001
CLIP	0.656	0.582-0.730	< 0.001
12-mo
GPS	0.676	0.604-0.747	< 0.001
mGPS	0.665	0.592-0.738	< 0.001
PI	0.652	0.577-0.726	< 0.001
NLR	0.590	0.513-0.667	0.024
PNI	0.527	0.450-0.605	0.495
PLR	0.537	0.460-0.615	0.346
TNM	0.651	0.576-0.725	< 0.001
BCLC	0.656	0.584-0.729	< 0.001
CLIP	0.711	0.644-0.778	< 0.001
24-mo
GPS	0.687	0.601-0.772	< 0.001
mGPS	0.684	0.601-0.767	< 0.001
PI	0.682	0.599-0.766	< 0.001
NLR	0.593	0.498-0.688	0.063
PNI	0.512	0.415-0.609	0.808
PLR	0.554	0.457-0.652	0.279
TNM	0.706	0.621-0.791	< 0.001
BCLC	0.656	0.572-0.741	0.002
CLIP	0.721	0.644-0.797	< 0.001

BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; CLIP: Cancer of the Liver Italian Program; GPS: Glasgow Prognostic Score; mGPS: Modifed Glasgow Prognostic Score; NLR: Neutrophil lymphocyte ratio; PI: Prognostic index; PLR: Platelet-lymphocyte ratio; PNI: Prognostic nutritional index; TNM: Tumor-node-metastasis.

Table 5 Combined score of the Glasgow Prognostic Score and Cancer of the Liver Italian Program score

Variables	Score
Variables	0	1	2
Child-Pugh stage	A	B	C
Tumor morphology	Uninodular and extension ≤ 50%	multinodular and extension ≤ 50%	multinodular or extension > 50%
AFP (ng/mL)	< 400	≥ 400
Portal vein thrombosis	No	Yes
GPS	CRP ≤ 10 mg/L and albumin ≥ 35 g/L	(CRP ≤ 10 mg/L and albumin < 35 g/L) or (CRP > 10 mg/L and albumin ≥ 35 g/L)	CRP > 10 mg/L and albumin < 35 g/L

AFP: Alpha-fetoprotein level; CRP: C-reactive protein.

Citation: Zhou DS, Xu L, Luo YL, He FY, Huang JT, Zhang YJ, Chen MS. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol 2015; 21(18): 5582-5590
URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5582.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5582